Researchers at a major 2026 international cancer conference presented multiple new treatments for women’s cancers, including targeted drugs called antibody-drug conjugates and immunotherapy approaches that help the body fight cancer. According to Gram Research analysis of presentations from over 1,270 cancer specialists, these personalized treatments, selected using blood tests that identify cancer biomarkers, show promise for ovarian, endometrial, and cervical cancers and may become standard options within the next few years.
At a major medical conference in Copenhagen in June 2026, cancer doctors from around the world shared exciting news about new ways to treat women’s cancers. Researchers presented studies on new drugs called antibody-drug conjugates that work like targeted missiles, attacking cancer cells while sparing healthy ones. They also discussed immunotherapy, which helps the body’s own immune system fight cancer, and new blood tests that can help doctors pick the best treatment for each patient. According to Gram Research analysis, these advances could change how doctors treat ovarian, endometrial, and cervical cancers in the coming years.
Key Statistics
A 2026 European Society for Medical Oncology conference reviewed 171 scientific abstracts and 16 major presentations on new cancer treatments, with over 1,270 cancer specialists from 70+ countries attending to discuss antibody-drug conjugates and immunotherapy advances for women’s cancers.
The 2026 gynecological cancer conference highlighted new biomarker-guided treatment tools like KELIM and circulating immune signatures that use blood tests to personalize cancer therapy selection, moving away from one-size-fits-all treatment approaches.
Researchers presented data on antibody-drug conjugates targeting four different cancer cell markers, folate receptor alpha, HER2, B7-H4, and nectin-4, as part of a shift toward precision medicine in treating ovarian, endometrial, and cervical cancers.
The Quick Take
- What they studied: New cancer treatments and ways to identify which patients will benefit most from specific drugs for women’s cancers like ovarian, endometrial, and cervical cancer
- Who participated: Over 1,270 cancer doctors and researchers from more than 70 countries attended the conference and reviewed 171 scientific studies presented at the meeting
- Key finding: Multiple new targeted drugs and immunotherapy approaches showed promise in treating different types of women’s cancers, with special focus on personalized medicine using blood tests and biomarkers
- What it means for you: If you or a loved one has been diagnosed with a women’s cancer, these new treatments may become available options in the coming years. Talk to your doctor about whether you might be eligible for clinical trials testing these newer approaches
The Research Details
This was a conference summary reviewing the most important presentations from the European Society for Medical Oncology’s Gynecological Cancers Congress held in Copenhagen, Denmark from June 17-19, 2026. The conference brought together cancer specialists from around the world to share their latest research findings. The summary focuses on oral presentations, talks given by researchers about their studies, rather than poster presentations. This included 6 formal research papers and 10 rapid-fire presentations of the most exciting new findings.
The presentations covered three main areas: new antibody-drug conjugates (special drugs that target cancer cells), immunotherapy (treatments that boost the body’s immune system), and biomarkers (biological signs that help doctors predict which patients will respond best to which treatments). Researchers presented data on drugs targeting different cancer cell markers like folate receptor alpha, HER2, B7-H4, and nectin-4, essentially different ‘handles’ on cancer cells that doctors can use to attack them.
The conference also highlighted new tools for personalizing cancer treatment, including something called KELIM and circulating immune signatures, which are blood tests that can help doctors understand each patient’s unique cancer and choose the best treatment accordingly.
This research approach matters because it shows the current direction of cancer medicine: moving away from one-size-fits-all treatments toward personalized medicine. By reviewing the latest presentations from leading cancer researchers worldwide, we can see what treatments are closest to helping patients. The emphasis on biomarkers and patient selection tools is particularly important because it means doctors are learning to match the right drug to the right patient, potentially improving outcomes and reducing unnecessary side effects.
This is a summary of presentations at a major international medical conference, which means the research has been vetted by a scientific committee before being selected for presentation. However, this is not a single research study but rather a review of multiple studies. Some of the presented research may still be in early stages and not yet published in peer-reviewed journals. The findings represent the current state of research but should be considered preliminary until individual studies are published in detail. The conference included over 1,270 participants from 70+ countries, suggesting broad international scientific input and validation.
What the Results Show
The conference highlighted several new antibody-drug conjugates, drugs designed to deliver cancer-killing medicine directly to cancer cells while minimizing harm to healthy cells. These drugs target different markers on cancer cells, including folate receptor alpha (found on many ovarian cancers), HER2 (found on some breast and ovarian cancers), B7-H4 (an immune checkpoint), and nectin-4 (found on some cancers). Early data presented suggests these targeted drugs may be more effective than traditional chemotherapy for certain patients.
Immunotherapy approaches also showed promise, particularly in endometrial cancer (cancer of the uterus lining) and cervical cancer. These treatments work by removing the ‘brakes’ that cancer cells put on the immune system, allowing the body’s natural defenses to attack the cancer. Researchers presented data showing that combining immunotherapy with other treatments may work better than either approach alone.
A major theme was the importance of biomarkers, biological signs in blood or tissue that predict which patients will respond to which treatments. New tools like KELIM and circulating immune signatures are blood tests that can identify these markers without invasive biopsies. This allows doctors to personalize treatment selection, potentially improving outcomes while reducing unnecessary treatments for patients unlikely to benefit.
The conference emphasized that the future of gynecologic cancer treatment lies in matching the right drug to the right patient based on their cancer’s specific characteristics, rather than using the same treatment for all patients with the same cancer type.
Additional presentations discussed combination strategies, using multiple drugs together to improve effectiveness. Researchers also presented data on managing side effects from these new treatments and improving quality of life for patients undergoing cancer therapy. Studies on how to identify patients most likely to benefit from immunotherapy, based on their immune system characteristics, were also highlighted. The conference included discussion of how to make these new treatments accessible globally, recognizing that many patients in developing countries may not have immediate access to cutting-edge therapies.
These findings represent a significant evolution from previous cancer treatment approaches. Traditional chemotherapy drugs attack all rapidly dividing cells, which is why they cause significant side effects. The new antibody-drug conjugates are more targeted, attacking specific markers on cancer cells. Immunotherapy is also newer, it represents a shift from directly killing cancer cells to empowering the body’s own immune system. Previous research showed that one-size-fits-all treatment approaches left many patients receiving ineffective therapy. The emphasis on biomarkers and personalized medicine builds on growing evidence that cancer is not one disease but many different diseases that require different treatments. These conference presentations show that the field is moving toward precision medicine, the right treatment for the right patient at the right time.
This is a conference summary, not a detailed analysis of individual studies, so specific statistical details may be limited. Some of the research presented may be preliminary and not yet published in peer-reviewed journals, meaning the findings haven’t undergone the full scientific review process. The conference focused on oral presentations, which may represent the most exciting or preliminary findings rather than a comprehensive review of all research in the field. Sample sizes and follow-up periods for individual studies presented were not detailed in this summary. Additionally, most cutting-edge cancer treatments are currently available only in developed countries or through clinical trials, so these advances may not be immediately accessible to all patients worldwide.
The Bottom Line
If you have been diagnosed with ovarian, endometrial, or cervical cancer, ask your oncologist about: (1) whether you might be eligible for clinical trials testing these new antibody-drug conjugates or immunotherapy approaches, (2) biomarker testing to personalize your treatment plan, and (3) the timeline for when these newer treatments might become available as standard options. These recommendations have moderate to strong evidence from early research but should be discussed with your individual care team. Do not delay standard treatment while waiting for newer options unless your doctor recommends it.
Women with ovarian, endometrial, or cervical cancer diagnoses should pay attention to these advances, as should their family members and caregivers. Oncologists and gynecologic cancer specialists should be aware of these emerging treatments for patient discussions. Women at high risk for these cancers may want to discuss screening and prevention strategies with their doctors. However, these findings do not apply to people without cancer diagnoses: they are not preventive treatments for healthy individuals.
Many of these treatments are currently in clinical trials or early approval stages. Some may become available as standard treatment options within 1-3 years, while others may take 5+ years to reach widespread use. The timeline depends on regulatory approval, clinical trial results, and manufacturing scale-up. Patients interested in accessing these treatments sooner should ask their doctors about clinical trial opportunities.
Frequently Asked Questions
What are antibody-drug conjugates and how do they treat cancer?
Antibody-drug conjugates are targeted drugs that work like guided missiles, they carry cancer-killing medicine directly to cancer cells while sparing healthy cells. They attach to specific markers on cancer cells (like folate receptor alpha or HER2) and deliver their payload only to those cells, reducing side effects compared to traditional chemotherapy.
Can blood tests help doctors choose the best cancer treatment for me?
Yes. New biomarker tests like KELIM and circulating immune signatures analyze blood samples to identify characteristics of your specific cancer. This information helps doctors predict which treatments will work best for you personally, allowing for personalized medicine rather than treating all patients with the same cancer type identically.
When will these new cancer treatments be available to patients?
Many of these treatments are currently in clinical trials or early approval stages. Some may become standard treatment options within 1-3 years, while others may take longer. Ask your oncologist about clinical trial opportunities if you’re interested in accessing these newer approaches sooner than standard availability.
Is immunotherapy the same as chemotherapy for cancer?
No. Chemotherapy directly kills cancer cells but also damages healthy cells, causing side effects. Immunotherapy works differently, it removes the ‘brakes’ that cancer cells place on your immune system, allowing your body’s natural defenses to attack the cancer. The two approaches can sometimes be combined for better results.
Should I wait for these new treatments instead of starting standard cancer treatment?
No. Do not delay standard, proven treatments while waiting for newer options. Discuss with your oncologist whether you might be eligible for clinical trials testing newer treatments alongside or instead of standard therapy. Your doctor can help determine the best timing and approach for your specific situation.
Want to Apply This Research?
- If enrolled in a clinical trial or receiving one of these newer treatments, track weekly: (1) energy levels (1-10 scale), (2) side effects experienced and severity, (3) any blood work or biomarker test results, and (4) appointments and treatment dates. This data helps your care team monitor your response and adjust treatment if needed.
- Work with your oncology team to: (1) request biomarker testing if not already done, (2) ask specifically about clinical trials for newer antibody-drug conjugates or immunotherapy, (3) maintain detailed records of your treatment response and side effects, and (4) schedule regular follow-up appointments to monitor progress with new treatment approaches.
- Long-term tracking should include: monthly check-ins on treatment tolerance and side effects, quarterly biomarker or imaging assessments to measure treatment response, documentation of any changes in symptoms or quality of life, and regular communication with your oncology team about how you’re responding. Use the app to set reminders for appointments and to track patterns in how you feel over time, which can help your doctor adjust your care plan.
This article summarizes research presented at a medical conference and is for educational purposes only. It is not medical advice. Cancer treatment decisions should always be made in consultation with your oncologist or gynecologic cancer specialist who understands your individual medical history, cancer type, and stage. Some treatments discussed may still be in clinical trials and not yet approved for standard use. Do not delay or change your current cancer treatment based on this information without discussing it with your care team. If you have been diagnosed with cancer, speak with your doctor about whether you might be eligible for clinical trials or newer treatment approaches.
This research translation is published by Gram Research, the science division of Gram, an AI-powered nutrition tracking app.
